USDAnalytics has released new research examining how expanding injectable GLP-1 product presentations are influencing drug delivery device development, manufacturing quality and commercial supply requirements. Pharmaceutical manufacturers are introducing different dose strengths and injection formats, creating additional requirements for qualified containers, delivery mechanisms and finished drug-device configurations. According to USDAnalytics, the global GLP-1 Injectable Drug Delivery Devices Market is valued at USD 3.95 billion in 2026 and is projected to reach USD 9.30 billion by 2034, registering an 11.3% CAGR during 2026–2034.
To explore the research findings, request a sample: GLP-1 Injectable Drug Delivery Devices Market Research Sample
New Injection Presentations Create Additional Device Qualification Requirements
Recent regulatory approvals illustrate how injectable incretin medicines are expanding into different delivery presentations.
On February 23, 2026, Eli Lilly announced that the U.S. Food and Drug Administration had approved a label expansion for Zepbound (tirzepatide) to include a four-dose KwikPen for single-patient use.
According to the official Eli Lilly announcement, the multi-dose pen provides four administrations from one device, representing a different delivery configuration from the medicine's existing single-dose vial presentation.
The development introduces specific requirements involving cartridge compatibility, repeated dose delivery, needle interfaces and device functionality across the intended treatment period.
Separately, on March 19, 2026, the FDA approved Wegovy HD, a higher-dose 7.2 mg semaglutide injection manufactured by Novo Nordisk.
The FDA approval announcement confirmed the additional approved injectable presentation. The accompanying product labeling identifies the 7.2 mg presentation as a single-dose prefilled pen.
These developments demonstrate how pharmaceutical product portfolios can require different device configurations, container specifications and manufacturing arrangements.
The commercial implications extend to component qualification, production scheduling and the availability of validated device assembly processes.
Injection Device Quality Connects Pharmaceutical and Engineering Requirements
GLP-1 injection devices combine pharmaceutical formulations with mechanical systems designed to deliver specified doses under defined operating conditions.
Their development involves pharmaceutical container compatibility, mechanism performance, usability assessment and manufacturing controls.
Differences in formulation, injection volume or drug presentation can affect the selection and qualification of device components.
Manufacturing quality requirements also extend across organizations involved in component production, pharmaceutical filling and finished-device assembly.
The FDA's Quality Management System Regulation, effective February 2, 2026, incorporated ISO 13485:2016 into the applicable U.S. medical device quality framework.
Drug-device combination products are additionally subject to relevant pharmaceutical manufacturing and combination-product requirements.
In August 2026, the FDA also updated its human-factors and usability engineering guidance, reinforcing the importance of evaluating device interaction and potential use-related risks.
These requirements contribute to the technical and commercial responsibilities associated with pharmaceutical injection systems.
Device manufacturers increasingly support pharmaceutical partners through platform development, qualification activities, manufacturing engineering and long-term component supply.
As injectable product portfolios expand, commercial device supply depends on the coordination of approved product presentations with reliable manufacturing processes and applicable quality requirements.
USDAnalytics research highlights the role of delivery architecture, validated manufacturing capacity and drug-device integration in shaping the industry.
The complete USDAnalytics GLP-1 Injectable Drug Delivery Devices Market report provides detailed coverage of injection technologies, device manufacturers, industry developments and market forecasts through 2034.
Media Contact:
Harry James
Sales Manager
USD Analytics
+1 213-510-3499
sales@usdanalytics.com
www.usdanalytics.com
###